1Broome U,Olsson R,Loof L,et al.Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.Gut,1996,38:610-615.
3Graziadei IW,Wiesner RH,Marotta PJ,et al.Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis.Hepatology,1999,30:1121-1127.
4Boberg KM,Aadland E,Jahnsen J,et al.Incidence and prevalence of primary biliary cirrhosis,primary sclerosing cholangitis,and autoimmune hepatitis in a Norwegian population.Scand J Gastroenterol,1998,33:99-103.
5Escorsell A,Pares A,Rodes J,et al.Epidemiology of primary sclerosing cholangitis in Spain.Spanish Association for the Study of the Liver.J Hepatol,1994,21:787-791.
6Kingham JG,Kochar N,Gravenor MB.Incidence,clinical patterns,and outcomes of primary sclerosing cholangitis in South Wales,United Kingdom.Gastroenterology,2004,126:1929-1930.
7Farrant JM,Hayllar KM,Wilkinson ML,et al.Natural history and prognostic variables in primary sclerosing cholangitis.Gastroenterology,1991,100:1710-1717.
8Helzberg JH,Petersen JM,Boyer JL.Improved survival with primary sclerosing cholangitis.A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients.Gastroenterology,1987,92:1869-1875.
9Brandsaeter B,Schrumpf E,Bentdal O,et al.Recurrent primary sclerosing cholangitis after liver transplantation:a magnetic resonance cholangiography study with analyses of predictive factors.Liver Transpl,2005,11:1361-1369.
10Qiao L,Yacoub A,Studer E,et al.Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes.Hepatology,2002,35:779-789.
2Jadad A R,Moore R A,Carroll D,et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary[J]? Control Clin Trials,1986,17(1):1-12.
3Beuers U,Spengler U,Kruis W,et al.Ursodeoxycholic acid for treatment of primary sclerosing cholangitis:a placebo-controlled trial[J].Hepatology,1992,16(3):707-714.
4Lo S K,Herrmann R,Chapman R W,et al.Ursodooxycholic acid in primary sclerosing cholangitis:a double-blind placebo controlled trial[J].Hepatology,1992,16(Pt 2):92A.
5Stiehl A,Walker S,Stiehl L,et al.Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing eholangitis.A 3-year pilot study with a placebo-controlled study period[J].J Hepatol,1994,20(1):57-64.
6De Maria N,Colantoni A,Rosenbloom E,et al.Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period[J].Hepatogastroenterology,1996,43(12):1472-1479.
8Lindnr K D,for the Mayo Primary Sclerosing CholangitisUrsodeoxycholic Acid Study Group.Ursodiol for primary sclerosing cholangitis[J].N Engl J Med,1997,336(10):691-695.
9Mitchell S A,Bansi D S,Hunt N,et al.A preliminary trial of highdose.ursodeoxycholic acid in primary sclerosing cholangitis[J].Gastroenterology,2001,121 (4):900-907.
10Olsson R,Boberg K M,de Muckadell O S,et al.High-dose ursodeoxycholic acid in primary sclerosing cholangitis:a 5-year multicenter,randomized,controlled study[J].Gastroenterology,2005,129(5):1464-1472.
